To amend the market name of genetically altered salmon in the United States, and for other purposes.

IN THE SENATE OF THE UNITED STATES

JULY 11, 2017

Ms. Murkowski (for herself, Mr. Sullivan, Ms. Cantwell, and Mr. Merkley) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the market name of genetically altered salmon in the United States, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Genetically Engineered Salmon Labeling Act”.

SEC. 2. PURPOSES.

It is the purpose of this Act to—

(1) ensure that consumers in the United States can make informed decisions when purchasing salmon; and
(2) authorize an independent scientific and technical advisory organization to conduct a review of—

(A) the possible effects of genetically engineered salmon on wild salmon stocks; and

(B) the Food and Drug Administration’s approval of genetically engineered salmon for human consumption.

SEC. 3. MARKET NAME FOR GENETICALLY ENGINEERED SALMON.

(a) IN GENERAL.—Notwithstanding any other provision of law, for purposes of applying the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 301 et seq.), the acceptable market name of any salmon that is genetically engineered shall include the words “Genetically Engineered” or “GE” prior to the existing acceptable market name.

(b) DEFINITION.—For purposes of this section, salmon is genetically engineered if it has been modified by recombinant DNA (rDNA) techniques, including the entire lineage of salmon that contain the rDNA modification.

SEC. 4. THIRD-PARTY REVIEW OF CERTAIN SALMON APPROVAL.

(a) INDEPENDENT SCIENTIFIC ORGANIZATION REVIEW AND REPORT.—The Secretary of Health and
Human Services (referred to in this section as the "Secretary") shall ensure that the National Academy of Sciences, or a similar independent scientific and technical advisory organization, conducts a review of, and submits to the Secretary a report on—

(1) the environmental assessment carried out by the Food and Drug Administration and released on November 12, 2015, in support of approval of the new animal drug application under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b) with respect to AquAdvantage Salmon, taking into account the impact of AquAdvantage Salmon on wild stocks of salmon and related wild ecosystems; and

(2) each environmental assessment carried out by the Food and Drug Administration in support of an approval of a new animal drug application under section 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b) related to a genetically engineered finfish intended for human consumption.

(b) SECOND FDA ENVIRONMENTAL ASSESSMENT.—After receipt of a report under paragraph (1) or (2) of subsection (a), the Secretary shall conduct a second environmental assessment with respect to approval of the ap-
application described in such paragraph (1) or (2), taking
into account the findings in such report.

(c) EFFECTIVE DATE OF APPROVAL.—Notwith-
standing any other provision of law, the approval of a new
animal drug application with respect to which review of
an environmental assessment is required under subsection
(a) shall not take effect until the Secretary completes a
second environmental assessment under subsection (b).